Taiwan As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its COVID-19 vaccine, representing a debut on two fronts. Not only is this the first time a COVID-19 vaccine developed by…
Switzerland Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies’ global healthcare businesses. Michael Hübner, Early Innovation Partnering Lead and member of the Swiss Johnson & Johnson Leadership Team discusses how they support breakthrough early innovation…
Japan Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced countries – has lagged behind in terms of VC funding, especially in the life sciences and how this can be…
Switzerland In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders and start-ups in Europe, highlighted how the European VC & the Switzerland Biotech Investment space has evolved over the past decade and the funding challenges that remain. He also…
Switzerland Redalpine Venture Partners’ Dr Michael Sidler highlights some of the key trends in the European biotech VC space, the funding and operational strategies that successful start-ups in Europe are utilising, and the Swiss innovation ecosystem. What has happened in Europe over the last couple of decades has been truly…
Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing Medigen…
Taiwan Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have chosen a tried and tested technology platform as novel vaccine technologies face novel challenges Charles, could you start by introducing…
Sweden Ascelia Pharma is a Swedish oncology start-up based in Malmö. CEO Magnus Corfitzen talks about the opportunities they have found in the orphan oncology drug market, the promising phase III study for their lead asset, Mangoral, and his journey navigating the Swedish life science industry. With Mangoral, we are…
Spain Joël Jean-Mairet, general partner of Ysios Capital, discusses the major trends impacting the venture capital ecosystem in the life sciences sector and the complexity of attracting new investors to the market. Furthermore, he highlights the firm’s success stories and the key steps required for Spain to be a biotech hub…
China Dr. Tang Dajie, founder and CEO of investment vehicle Triwise Capital, discusses the numerous investment opportunities in Shenzhen’s life sciences sector and the city’s unique geographical and economic positioning. Dr. Tang, could you start by introducing your investment company, Triwise Capital, and the reason for its special focus on the…
Mexico Hernán Fernández, Managing Partner at Angel Ventures, showcases the crucial role of private investments to enhance the national healthcare system as well as explains his action plan to raise the funds for the first regional venture capital fund in Latin America. Mr. Fernández, what are the points that triggered you…
Switzerland Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an increasing number of Swiss biotechs are looking towards the US for funding; a trend that risks destabilising and weakening the…
See our Cookie Privacy Policy Here